Antibiotic consumption, course of therapy and costs in primary care of GP, pediatric and ENT practices

Antibiotic consumption, course of therapy and costs in primary care of GP, pediatric and ENT practices - HaHNOPAKT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033456

Enrollment

730

Registered

2024-04-12

Start date

2024-05-21

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H65.0 H65.1 H66.0 J00 J01 J02.8 J02.9 J03.8 J03.9 J04 J06

Interventions

Group 1: GP, pediatric and ENT practices with a conventional treatment focus: Documentation of the antibiotic prescription on day 0, the medication actually taken up to day 7, the course of symptoms u

Eligibility

Sex/Gender

All

Age

6 Months to No maximum

Inclusion criteria

Inclusion criteria: - Planned medication therapy due to URTI/AO infections - Legal capacity (for children and adolescents: legal capacity of the legal guardian) - Adults: voluntary written declaration of consent - Adolescents between 14 and 17 years inclusive: Voluntary written declaration of consent by the legal guardian(s) and voluntary written declaration of assent by the adolescent(s); - Children from 6 years up to and including 13 years: voluntary written declaration of consent by the legal guardian(s) and voluntary assent from the child documented in the patient file; - Children from 6 months up to and including 5 years of age: voluntary written declaration of consent by the legal guardian(s)

Exclusion criteria

Exclusion criteria: - Clinically relevant concomitant diseases that inadmissibly impair the assessment of the prescription of drug therapies for the above-mentioned indications or the allocation of the documented disease and therapy-related symptoms to the same. - Participation in another clinical trial / taking an investigational product currently or within the last 4 weeks

Design outcomes

Primary

Measure	Time frame
Relevant improvement on day 7 after practice visit (PROM)	—

Secondary

Measure	Time frame
- Patient satisfaction with therapy on day 7 after practice visit - Presence of URTI/AO symptoms > grade 1 on day 7 after practice visit - Duration of illness until complete resolution of symptoms - Necessary follow-up visits to the practice - Frequency and severity of complications - Prescription/consumption of other medications	—

Countries

Germany

Contacts

Public ContactMarcus Reif

Gesellschaft für Klinische Forschung e.V.

marcus.reif@gkf-berlin.de+49303157440

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026